<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02090387</url>
  </required_header>
  <id_info>
    <org_study_id>BL20</org_study_id>
    <nct_id>NCT02090387</nct_id>
    <nct_alias>NCT02238600</nct_alias>
  </id_info>
  <brief_title>Evaluation of an Oral Nutritional Supplement on Lean Body Mass in Healthy Older Subjects.</brief_title>
  <official_title>Evaluation of a Complete Oral Nutritional Supplement on Lean Body Mass in Healthy Older Subjects During Bed Rest and Recovery.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott Nutrition</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abbott Nutrition</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will evaluate the effects of oral nutritional supplements (ONS) on attenuating the&#xD;
      lean body mass (LBM) loss that occurs after bed rest.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Actual">April 2016</completion_date>
  <primary_completion_date type="Actual">April 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total lean body mass</measure>
    <time_frame>Baseline to Study Day 10</time_frame>
    <description>Change from baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hand-grip strength</measure>
    <time_frame>Baseline, Study Day 10, Study Week 6 and 12</time_frame>
    <description>Change from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Short Physical Performance Battery (SPPB)</measure>
    <time_frame>Baseline, Study Day 10, Study Week 6 and 12</time_frame>
    <description>Change from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Isokinetic leg strength</measure>
    <time_frame>Baseline, Study Day 10 and Study Week 12</time_frame>
    <description>Change from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body Mass Index (BMI)</measure>
    <time_frame>Screening Visits 1 and 3; Baseline; Study Days 2, 4, 6, 8 and 10; Study Weeks 3, 6, 9 and 12</time_frame>
    <description>Calculated BMI = weight/height2 (kg/m2).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lower extremity lean mass</measure>
    <time_frame>Baseline, Study Day 10, Study Weeks 6 and 12</time_frame>
    <description>Measured by DXA; Change from baseline</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">76</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Control ONS</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>ONS without AN777</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Investigational ONS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ONS containing AN777</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>ONS without AN777</intervention_name>
    <description>2 servings a day</description>
    <arm_group_label>Control ONS</arm_group_label>
    <other_name>Commercially available ONS</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>ONS containing AN777</intervention_name>
    <description>2 servings a day</description>
    <arm_group_label>Investigational ONS</arm_group_label>
    <other_name>Investigational ONS</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age ≥ 60 to ≤ 79 years&#xD;
&#xD;
          2. Body Mass Index (BMI) &gt;20 but ≤ 35 kg/m2.&#xD;
&#xD;
          3. Short Physical Performance Battery (SPPB) score of &gt; 9 (fully functional with no&#xD;
             mobility limitations).&#xD;
&#xD;
          4. Triacylglyceride (TAG) level is ≤ 250 mg/dl, LDL cholesterol is ≤ 155 mg/dl, total&#xD;
             cholesterol level is ≤ 250 mg/dl.&#xD;
&#xD;
          5. Compliance with the various activity levels required for this study.&#xD;
&#xD;
          6. Ankle brachial index within the normal range, between 1 and 1.4.&#xD;
&#xD;
          7. Physical activity score within the 2008 Guidelines for Americans.&#xD;
&#xD;
          8. Normal-good handgrip strength.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Type I or Type II Diabetes Mellitus.&#xD;
&#xD;
          2. Fasting blood glucose level of &gt;115 mg/dl.&#xD;
&#xD;
          3. Major surgery, less than 6 weeks prior to enrollment in the study, or subject has&#xD;
             planned elective surgery requiring 2 or more days of hospitalization.&#xD;
&#xD;
          4. History of pressure ulcers.&#xD;
&#xD;
          5. Stated history of Deep Vein Thrombosis (DVT), recent elevated D-dimer test, a positive&#xD;
             ultrasound for DVT, pulmonary embolism, carotid atherosclerosis, transient ischemic&#xD;
             attack (TIA), or stated hypercoaguable condition, or other clotting or bleeding&#xD;
             disorders, or is currently prescribed blood thinners.&#xD;
&#xD;
          6. Varicose veins that would result in significant discomfort while wearing TED hose&#xD;
             and/or SCD.&#xD;
&#xD;
          7. Stated autoimmune disease or active malignant disease.&#xD;
&#xD;
          8. Estimated glomerular filtration rate is &lt; 50ml/min/1.73m2.&#xD;
&#xD;
          9. Current significantly impaired liver function or hepatic enzyme tests are ≥2.5 times&#xD;
             normal limit.&#xD;
&#xD;
         10. Significant cardiovascular event ≤ 6 months prior to screening visit; or stated&#xD;
             history of congestive heart failure.&#xD;
&#xD;
         11. Untreated hypo- or hyper-thyroidism, or other endocrinopathies associated with&#xD;
             excessive androgen secretion.&#xD;
&#xD;
         12. Refractory anemia with hemoglobin value &lt;11.0 g/dl.&#xD;
&#xD;
         13. Chronic, contagious, infectious disease, such as active tuberculosis, hepatitis B or&#xD;
             C, or HIV.&#xD;
&#xD;
         14. Current infection (requiring prescription antimicrobial or antiviral medication, or&#xD;
             hospitalization), or has received corticosteroid treatment (with the exception of&#xD;
             inhaled or topical steroids) in the last 3 months.&#xD;
&#xD;
         15. Currently being prescribed pain/anti-inflammatory medication and/or is regularly&#xD;
             consuming over the counter pain/anti-inflammatory medication for chronic, or&#xD;
             persistent, pain, including but not limited to arthritic conditions, fibromyalgia, and&#xD;
             continuous localized pain.&#xD;
&#xD;
         16. History of allergy to any of the ingredients in the study products.&#xD;
&#xD;
         17. Deleted&#xD;
&#xD;
         18. Obstruction of the gastrointestinal tract precluding ingestion of the study product,&#xD;
             inflammatory bowel disease, short bowel syndrome or other severe forms of&#xD;
             gastrointestinal disease.&#xD;
&#xD;
         19. Stated uncontrolled severe diarrhea, nausea or vomiting.&#xD;
&#xD;
         20. Amputee.&#xD;
&#xD;
         21. Actively pursuing weight loss or gain.&#xD;
&#xD;
         22. Cannot refrain from taking medications/dietary supplements (all forms)/substances that&#xD;
             could modulate metabolism or body weight.&#xD;
&#xD;
         23. Cannot refrain from taking long chain n-3 polyunsaturated fatty acids (PUFA)&#xD;
             (eicosapentaenoic acid (EPA) ± docosahexaenoic acid (DHA) ± α-linolenic acid (ALA)),&#xD;
             or vitamin D, at levels that are significantly higher than the established Acceptable&#xD;
             Macronutrient Distribution Range (AMDR), or recommended by the American Heart&#xD;
             Association (500 mg/d total EPA+DHA), during the study.&#xD;
&#xD;
         24. Cannot refrain from smoking or discontinue the use of nicotine (all forms including&#xD;
             patches) or tobacco during the study.&#xD;
&#xD;
         25. One or more metal implants.&#xD;
&#xD;
         26. Currently diagnosis or a history of severe dementia or delirium, eating disorder,&#xD;
             history of significant neurological or psychiatric disorder, alcoholism, substance&#xD;
             abuse or other conditions that may interfere with study product consumption or&#xD;
             compliance.&#xD;
&#xD;
         27. Cannot abstain from alcohol use during the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Owen Kelly, Ph.D</last_name>
    <role>Study Chair</role>
    <affiliation>Abbott Nutrition</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Arkansas for Medical Sciences (UAMS)</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205-7199</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Hospital Translational Research Institute for Metabolism and Diabetes</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32804</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center of Translational Research in Aging &amp; Longevity</name>
      <address>
        <city>College Station</city>
        <state>Texas</state>
        <zip>77843-4253</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <study_first_submitted>March 17, 2014</study_first_submitted>
  <study_first_submitted_qc>March 17, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 18, 2014</study_first_posted>
  <last_update_submitted>July 7, 2016</last_update_submitted>
  <last_update_submitted_qc>July 7, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 11, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

